Cargando…

Effects of somatostatin analog treatment on cardiovascular parameters in patients with acromegaly: A systematic review

BACKGROUND: There is a belief that in patients with acromegaly, first-generation somatostatin analogs (SSAs) might improve cardiovascular (CV) structure and function. However, most published clinical trials involved only a few patients and their results are rather variable. We aimed to conduct a sys...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heidarpour, Maryam, Shafie, Davood, Aminorroaya, Ashraf, Sarrafzadegan, Nizal, Farajzadegan, Ziba, Nouri, Rasool, Najimi, Arash, Dimopolou, Christina, Stalla, Gunter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521613/ https://www.ncbi.nlm.nih.gov/pubmed/31143230 http://dx.doi.org/10.4103/jrms.JRMS_955_18

Ejemplares similares

Resistance to Somatostatin Analogs in Italian Acromegaly Patients: The MISS Study
por: Berton, Alessandro Maria, et al.
Publicado: (2022)

Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
por: Machado-Alba, J. E., et al.
Publicado: (2022)

Design and methodology of heart failure registry: Results of the Persian registry of cardiovascular disease
por: Givi, Mahshid, et al.
Publicado: (2019)

Relation between Hemoconcentration Status and Readmission Plus Mortality Rate Among Iranian Individuals with Decompensated Heart Failure
por: Yadollahi Farsani, Ashkan, et al.
Publicado: (2020)

Acromegaly: Pathophysiological Considerations and Treatment Options Including the Evolving Role of Oral Somatostatin Analogs
por: Daniel, Charles P., et al.
Publicado: (2023)

Intrauterine device survival in Iranian women: systematic review and meta-analysis
por: Farajzadegan, Ziba, et al.
Publicado: (2015)

Efficacy of cabergoline add-on therapy in patients with acromegaly resistance to somatostatin analogs treatment and the review of literature
por: Kizilgul, Muhammed, et al.
Publicado: (2022)

Predictors of Quality of Life in Acromegaly: No Consensus on Biochemical Parameters
por: Geraedts, Victor J., et al.
Publicado: (2017)

The Future of Somatostatin Receptor Ligands in Acromegaly
por: Gadelha, Monica R, et al.
Publicado: (2021)

Insulin Resistance in Patients With Acromegaly
por: Vila, Greisa, et al.
Publicado: (2019)

Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
por: Neggers, Sebastian J. C. M. M., et al.
Publicado: (2011)

Place of Preoperative Treatment of Acromegaly with Somatostatin Analog on Surgical Outcome: A Systematic Review and Meta-Analysis
por: Pita-Gutierrez, Francisco, et al.
Publicado: (2013)

Treatment adherence and persistence with long-acting somatostatin analog therapy for the treatment of acromegaly: a retrospective analysis
por: Gurel, Michelle H., et al.
Publicado: (2017)

Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs
por: Gadelha, Mônica, et al.
Publicado: (2020)

Association of digoxin with mortality and rehospitalization in heart failure patients treated with beta-blockers: Results from the Persian Heart Failure Patient Registry
por: Yazdi, Maryam, et al.
Publicado: (2022)

Combined treatment of somatostatin analogues with pegvisomant in acromegaly
por: Franck, S. E., et al.
Publicado: (2015)

Novel Somatostatin Receptor Ligands Therapies for Acromegaly
por: Paragliola, Rosa Maria, et al.
Publicado: (2018)

Effectiveness of bosentan in the treatment of systemic sclerosis-related digital ulcers: Systematic review and meta-analysis
por: Hosseinbalam, Marziyeh, et al.
Publicado: (2023)

Acromegaly and papillary thyroid carcinoma: A case series
por: Heidarpour, Maryam, et al.
Publicado: (2019)

Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly
por: Venegas‐Moreno, Eva, et al.
Publicado: (2017)

Glycemic profile in patients with acromegaly treated with somatostatin analogue
por: Valea, A, et al.
Publicado: (2015)

Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement
por: Chin, Sang Ouk, et al.
Publicado: (2019)

Association of Pathology Markers with Somatostatin Analogue Responsiveness in Acromegaly
por: Kontogeorgos, George, et al.
Publicado: (2022)

AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients
por: Daly, Adrian F, et al.
Publicado: (2019)

Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
por: Kuhn, Emmanuelle, et al.
Publicado: (2020)

Patients Characteristics and Preliminary Outcomes of Heart Failure Registry in A Middle-Income Country: Persian Registry of Cardiovascular Disease/Heart Failure (PROVE/HF)
por: Givi, Mahshid, et al.
Publicado: (2018)

The Association of Thyroid-Stimulating Hormone (TSH) Levels and Lipid Profile in Euthyroid Patients with Familial Hypercholesterolemia
por: Heidarpour, Maryam, et al.
Publicado: (2023)

Two rare manifestations of primary hyperparathyroidism: paralysis and peptic ulcer bleeding
por: Heidarpour, Maryam, et al.
Publicado: (2017)

Correction to: Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
por: Kuhn, Emmanuelle, et al.
Publicado: (2020)

Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review
por: Cella, David, et al.
Publicado: (2021)

Metolazone Add-On Therapy in Heart Failure: A Cohort Study from Persian Registry of Cardiovascular Disease/Heart Failure (PROVE/HF)
por: Rahimi, Farzad, et al.
Publicado: (2021)

E‐cadherin expression is associated with somatostatin analogue response in acromegaly
por: Venegas‐Moreno, Eva, et al.
Publicado: (2019)

Epithelial–Mesenchymal Transition in the Resistance to Somatostatin Receptor Ligands in Acromegaly
por: Gil, Joan, et al.
Publicado: (2021)

Real-World Experience With Pasireotide Lar in Acromegaly Resistant to First-Generation Somatostatin Analogs: A Single Center 1-Year Observation
por: Stelmachowska-Banas, Maria, et al.
Publicado: (2021)

Effects of somatostatin analogs on uptake of radiolabeled somatostatin analogs on imaging: a systematic review and meta-analysis
por: Wang, Rang, et al.
Publicado: (2023)

Identification of somatostatin receptor type 5 gene polymorphisms associated with acromegaly
por: Ciganoka, Darja, et al.
Publicado: (2011)

The Effect of Long Acting Somatostatin Analogue SMS 201-995 in Acromegaly
por: Choi, Chul Joon, et al.
Publicado: (1987)

The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly
por: Colao, Annamaria, et al.
Publicado: (2015)

Active postoperative acromegaly: sustained remission after discontinuation of somatostatin analogues
por: Alvarez-Escola, Cristina, et al.
Publicado: (2016)

Attitudes and preferences in patients with acromegaly on long-term treatment with somatostatin analogues
por: Follin, Cecilia, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_2o0k9ku42htqmicp8u8ks3obkg